Expert Review of Neurotherapeutics最新文献_第6页

The latest therapeutic advances with spontaneous intracerebral hemorrhage. 自发性脑出血的最新治疗进展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-06-01 Epub Date: 2025-05-06 DOI: 10.1080/14737175.2025.2502048

Michael Griffin, Chun Shing Kwok, Adnan I Qureshi, Gregory Y H Lip

{"title":"The latest therapeutic advances with spontaneous intracerebral hemorrhage.","authors":"Michael Griffin, Chun Shing Kwok, Adnan I Qureshi, Gregory Y H Lip","doi":"10.1080/14737175.2025.2502048","DOIUrl":"10.1080/14737175.2025.2502048","url":null,"abstract":"Introduction: Intracerebral hemorrhage (ICH) accounts for 10% of strokes; however, compared with ischemic stroke, progress leading to novel treatments and improved patient outcomes has been lacking. Recently, there have been several promising developments and renewed research interest within the field. Positive results from randomized controlled trials have now been reported in multiple domains of care for patients with ICH. Anticoagulation-associated ICH is increasingly frequent, and clinicians deciding on reversal and timing of re-initiation of oral anticoagulation now have more therapeutic agents available and evidence to guide them. Minimally invasive techniques are also added to the neurosurgical arsenal, leading to improvements in functional outcomes. Acute treatment at presentation is best served by bundled care approaches, which ensure goal-directed management of blood pressure, glucose and temperature.Areas covered: This narrative review summarizes the recent developments in this area, as well as the current recommendations of key international guidelines. Literature search was carried out using PubMed database with priority given to publications since 2020.Expert opinion: There is renewed optimism for innovation in ICH. The standard of care for this condition now leads to improvements in mortality and long-term functional ability. Efforts to improve the patient selection and surgical techniques for operative management are ongoing.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"661-673"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Uncertainties in anti-amyloid monoclonal antibody therapy for Alzheimer's disease: the challenges ahead. 抗淀粉样蛋白单克隆抗体治疗阿尔茨海默病的不确定性：未来的挑战。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-06-01 Epub Date: 2025-05-05 DOI: 10.1080/14737175.2025.2500752

Madia Lozupone, Vittorio Dibello, Emanuela Resta, Rodolfo Sardone, Fabio Castellana, Roberta Zupo, Luisa Lampignano, Ilaria Bortone, Anita Mollica, Giuseppe Berardino, Mario Altamura, Antonello Bellomo, Antonio Daniele, Vincenzo Solfrizzi, Francesco Panza

{"title":"Uncertainties in anti-amyloid monoclonal antibody therapy for Alzheimer's disease: the challenges ahead.","authors":"Madia Lozupone, Vittorio Dibello, Emanuela Resta, Rodolfo Sardone, Fabio Castellana, Roberta Zupo, Luisa Lampignano, Ilaria Bortone, Anita Mollica, Giuseppe Berardino, Mario Altamura, Antonello Bellomo, Antonio Daniele, Vincenzo Solfrizzi, Francesco Panza","doi":"10.1080/14737175.2025.2500752","DOIUrl":"10.1080/14737175.2025.2500752","url":null,"abstract":"Introduction: Alzheimer's disease (AD), the leading cause of dementia, poses a significant burden on patients, caregivers, and healthcare systems worldwide. After two decades of extensive efforts, we are still without significantly effective disease-modifying drugs for AD. Although brain amyloid-β (Aβ) accumulation may predict cognitive decline, several drug candidates, including anti-Aβ monoclonal antibodies, have been developed and tested to reduce Aβ plaque burden effective, but without significant clinical success.Areas covered: The following review presents and discusses anti-Aβ monoclonal antibody therapeutics used to treat AD. The article considers both current approaches and alternatives. This article is multiple database searches (MEDLINE, EMBASE, Scopus, Ovid and Google Scholar) on all the available literature up to 1 February 2025.Expert opinion: Randomized clinical trials (RCTs) of anti-Aβ drugs in AD have not fully validated the Aβ cascade hypothesis. Nevertheless, eight anti-Aβ monoclonal antibodies have, thus far, made it to Phase III RCTs. Moving forward, the use of the Apolipoprotein E genotype and tau protein as alternative biomarkers can assist clinicians in providing patients with even more individualized and efficacious anti-Aβ monoclonal antibodies dosing regimens and reduce the risk of serious amyloid-related imaging abnormalities.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"649-659"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of botulinum neurotoxin-A in the treatment of neuropsychiatric symptoms in patients with Parkinson's disease: an open-label randomized controlled study. 肉毒杆菌神经毒素a治疗帕金森病患者神经精神症状的疗效：一项开放标签随机对照研究

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-06-01 Epub Date: 2025-05-06 DOI: 10.1080/14737175.2025.2500753

Xiaofeng Zhu, Xiu Yang, Ming Wei, Huayan Wang, Jun Shen, Qiu Han

{"title":"Efficacy of botulinum neurotoxin-A in the treatment of neuropsychiatric symptoms in patients with Parkinson's disease: an open-label randomized controlled study.","authors":"Xiaofeng Zhu, Xiu Yang, Ming Wei, Huayan Wang, Jun Shen, Qiu Han","doi":"10.1080/14737175.2025.2500753","DOIUrl":"10.1080/14737175.2025.2500753","url":null,"abstract":"Objectives: Parkinson's disease (PD) often presents with neuropsychiatric symptoms that worsen quality of life. The aim of this study was to evaluate the effectiveness of Botulinum neurotoxin-A (BTX-A) in managing neuropsychiatric manifestations in PD patients.Methods: Neuropsychiatric status was assessed in 185 PD patients using the Cornell Medical Index (CMI). Ninety-four patients exhibiting neuropsychiatric symptoms were randomly assigned to two groups: BTX-A (n=47, local injections) and citalopram (n=47, 10-40 mg/day). Outcomes were compared at baseline and 8 weeks post-treatment.Results: The authors findings revealed a significant reduction in somatization, tension, anxiety, depression, sensitivity, and overall scores in the BTX-A group at the eight-week follow-up (p < 0.05 for all). Notably, patients in the BTX-A group exhibited similar levels of somatization, depression, anxiety, maladjustment, sensitivity, anger, and overall scores compared to the citalopram group (p > 0.05 for all). Both groups reported comparable percentages of improvement in neuropsychiatric symptoms (75.6% vs. 82.6%, p = 0.57).Conclusions: This study demonstrates the potential of BTX-A in alleviating tension, anxiety, depression, sensitivity, and other neuropsychiatric symptoms in PD patients. Importantly, BTX-A's efficacy was comparable to that of citalopram, suggesting its potential as a viable therapeutic option for managing neuropsychiatric manifestations in PD.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"717-725"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological therapies for early and long-term recovery in disorders of consciousness: current knowledge and promising avenues. 意识障碍早期和长期恢复的药物治疗：目前的知识和有希望的途径。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-06-01 Epub Date: 2025-05-07 DOI: 10.1080/14737175.2025.2500757

Rosalie Girard Pepin, Fatemeh Seyfzadeh, David Williamson, Olivia Gosseries, Catherine Duclos

{"title":"Pharmacological therapies for early and long-term recovery in disorders of consciousness: current knowledge and promising avenues.","authors":"Rosalie Girard Pepin, Fatemeh Seyfzadeh, David Williamson, Olivia Gosseries, Catherine Duclos","doi":"10.1080/14737175.2025.2500757","DOIUrl":"10.1080/14737175.2025.2500757","url":null,"abstract":"Introduction: Disorders of consciousness (DoC) are characterized by impaired arousal and/or awareness, ranging from coma to unresponsive wakefulness syndrome, minimally conscious state, and cognitive motor dissociation. Pharmacological treatment options remain limited, complicated by the heterogeneity of etiologies, such as traumatic brain injury, stroke, and infections. The lack of rigorous clinical trials has led to off-label use of treatments, often without clear mechanistic understanding, posing challenges for effective patient care.Areas covered: In this perspective, the authors report on key studies concerning the effectiveness of pharmacological interventions, including dopaminergic and GABAergic agents, antidepressants, statins, and anticonvulsants, in promoting recovery of consciousness in DoC.Expert opinion: Robust longitudinal clinical trials are needed, with priority given to early subacute phase intervention. Outcomes should be better defined, considering immediate responses to medication while also increasing the emphasis on long-term quality of life. Unified functional and mechanistic frameworks are needed to guide research and foster collaboration. Furthermore, a shift toward personalized medicine would benefit this heterogeneous population. Moving forward, assessing the efficacy of more unconventional or 'paradoxical' pharmacological options in treatment plans will be essential. The authors also expect an increased use of AI tools to identify factors that best predict treatment responses.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"613-633"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unlocking the potential of virtual reality for post-stroke sensorimotor rehabilitation - are we any closer? 释放虚拟现实在中风后感觉运动康复中的潜力——我们离目标更近了吗？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-06-01 Epub Date: 2025-04-08 DOI: 10.1080/14737175.2025.2490535

Mindy F Levin, Jeroen B J Smeets

引用次数: 0

Advances in endovascular thrombectomy for the treatment of acute ischemic stroke. 血管内取栓治疗急性缺血性脑卒中的研究进展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-06-01 Epub Date: 2025-04-13 DOI: 10.1080/14737175.2025.2490538

David Lauer, Jakub Sulženko, Hana Malíková, Ivana Štětkářová, Petr Widimský

{"title":"Advances in endovascular thrombectomy for the treatment of acute ischemic stroke.","authors":"David Lauer, Jakub Sulženko, Hana Malíková, Ivana Štětkářová, Petr Widimský","doi":"10.1080/14737175.2025.2490538","DOIUrl":"10.1080/14737175.2025.2490538","url":null,"abstract":"Introduction: Acute ischemic stroke (AIS) is the second leading cause of death and one of the leading causes of long-term disability globally. Endovascular thrombectomy (EVT) has revolutionized treatment for large vessel occlusion (LVO), providing 20% increase in post-stroke functional independence compared to intravenous thrombolysis (IVT) alone. Despite its proven efficacy, EVT is underutilized. While it is suitable for at least 15-20% of AIS patients, its mean adoption ranges from less than 1% to 7% in different areas.Areas covered: This review highlights key findings from pivotal randomized controlled trials and real-world data, focusing on patient selection criteria, advancements in thrombectomy devices, and procedural innovations. A comprehensive literature search was performed using PubMed, Scopus, EMBASE and the Cochrane Library for relevant randomized controlled trials and observational studies.Expert opinion: Disparity in access to EVT requires strategic investments in healthcare systems and international multidisciplinary collaboration. Enhancing geographic coverage with thrombectomy-capable centers and optimizing prehospital triage systems are essential. Bridging the gap between treatment capability and real-world implementation is critical to improving global AIS outcomes.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"675-687"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correlation between systemic bleeding during thrombolysis and intracranial hemorrhage after thrombolysis in acute ischemic stroke. 急性缺血性脑卒中溶栓时全身性出血与溶栓后颅内出血的相关性。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-06-01 Epub Date: 2025-04-10 DOI: 10.1080/14737175.2025.2491674

Xin-Lei Mao, Si-Si He, Ya-Xi Zhang, Cai-Dan Lin, Xin-Xin Chen, Shi-Zheng Zhang, Li-Na Ge, Qing-Qing Zhuang

{"title":"Correlation between systemic bleeding during thrombolysis and intracranial hemorrhage after thrombolysis in acute ischemic stroke.","authors":"Xin-Lei Mao, Si-Si He, Ya-Xi Zhang, Cai-Dan Lin, Xin-Xin Chen, Shi-Zheng Zhang, Li-Na Ge, Qing-Qing Zhuang","doi":"10.1080/14737175.2025.2491674","DOIUrl":"10.1080/14737175.2025.2491674","url":null,"abstract":"Background: Current models primarily predict outcomes before thrombolytic therapy. This study explored if systemic bleeding during thrombolysis predicts hemorrhagic transformation (HT) within 36 hours post-thrombolysis.Research design and methods: Data from 591 acute ischemic stroke patients treated with rt-PA at Wenzhou Central Hospital (2016-2023) were prospectively collected and analyzed. The incidence of systemic bleeding was compared with the Stroke Prognostication using Age and the National Institutes of Health Stroke Scale (Span100) index, as well as the Hemorrhage After Thrombolysis (HAT) scale.Results: Systemic bleeding occurred in 285 patients, including 92 with HT. The HT rate was significantly higher in patients with late-onset oral bleeding (35.90%) or other systemic bleeding (38.89%) than in those without (p < 0.01). Late-onset oral and systemic bleeding during thrombolysis predicted HT in anterior circulation infarction (p < 0.001) but not in posterior circulation infarction (p = 0.70). The AUC for predicting HT was 0.578 for these bleeding types, versus 0.568 for Span-100 and 0.61 for HAT. Incorporating bleeding types increased Span-100 sensitivity to 0.623 and HAT to 0.648.Conclusions: Late-onset oral and other systemic bleeding during thrombolysis effectively predict HT in anterior circulation infarction, enhancing the sensitivity of Span100 and HAT scales when combined.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"727-735"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of the challenges with the differential diagnosis of schizotypal personality disorder. 精神分裂型人格障碍鉴别诊断的挑战概述。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-06-01 Epub Date: 2025-04-17 DOI: 10.1080/14737175.2025.2492379

Katherine V Raffensperger, Philip D Harvey

{"title":"An overview of the challenges with the differential diagnosis of schizotypal personality disorder.","authors":"Katherine V Raffensperger, Philip D Harvey","doi":"10.1080/14737175.2025.2492379","DOIUrl":"10.1080/14737175.2025.2492379","url":null,"abstract":"Introduction: Schizotypal personality disorder (SPD) has a long history, and there is still considerable ongoing research. Although there are overlapping features of SPD and other personality disorders, the full constellation of schizotypal features is broader. The longitudinal course of SPD is variable, with differences in trajectory manifesting lifelong clinical significance. Particularly important is the relationship between SPD and prodromal states that may result in an eventual diagnosis of psychosis.Areas covered: This review covers the history and differential diagnosis of SPD, including the older conceptualization of 'borderline schizophrenia.' Clinical, cognitive, functional, brain imaging, and genetic features of SPD, and the implications of age at onset and method of ascertainment of the condition are reviewed. Differences between psychometrically identified schizotypy, clinically diagnosed SPD, and other psychiatric conditions are described. A comprehensive literature search using MEDLINE (via PubMed) did not specify a date range, to capture the full scope of research.Expert opinion: SPD is unique in that the age at ascertainment is critical for the persistence of the diagnosis. When diagnosed with SPD in late adolescence, some individuals develop psychosis, some remit, and others have persistent, lifelong symptoms. Predictors of conversion to psychosis have been identified but are no proven treatments.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"689-698"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in stem cell-based therapeutic transfers for glioblastoma treatment. 干细胞转移治疗胶质母细胞瘤的研究进展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-06-01 Epub Date: 2025-04-21 DOI: 10.1080/14737175.2025.2490543

Mainak Bardhan, Muneeb Ahmad Muneer, Abhinav Khare, Rushita Minesh Shah, Anmol Kaur, Sonit Sai Vasipalli, Vinay Suresh, Vivek Podder, Manmeet Ahluwalia, Yazmin Odia, Zhijian Chen

{"title":"Advances in stem cell-based therapeutic transfers for glioblastoma treatment.","authors":"Mainak Bardhan, Muneeb Ahmad Muneer, Abhinav Khare, Rushita Minesh Shah, Anmol Kaur, Sonit Sai Vasipalli, Vinay Suresh, Vivek Podder, Manmeet Ahluwalia, Yazmin Odia, Zhijian Chen","doi":"10.1080/14737175.2025.2490543","DOIUrl":"10.1080/14737175.2025.2490543","url":null,"abstract":"Introduction: Glioblastoma (GBM), a highly malignant brain tumor, has a poor prognosis despite standard treatments like surgery, chemotherapy, and radiation. Glioblastoma stem cells (GSCs) play a critical role in recurrence and therapy resistance. Stem cell-based therapies have emerged as innovative approaches, leveraging the tumor-targeting abilities of stem cells to deliver treatments directly to GBM.Areas covered: This review focuses on using intact stem cells or subtypes for GBM therapy, excluding antigenic characteristics. The stem cell-based therapies explored include neural, mesenchymal, glioblastoma, hematopoietic and adipose-derived stem cells that have been investigated in both clinical and preclinical settings. A systematic search in PubMed, EMBASE, ClinicalTrials.gov, and Scopus had identified research up until January 2024. Key mechanisms reviewed include immune modulation, angiogenesis inhibition, and apoptosis induction. Discussion of completed and ongoing trials include emphasis on safety, efficacy, challenges, and study design limitations.Expert opinion: Stem cell-based therapies hold promise for treating GBM by targeting GSCs and improving treatment outcomes. Despite some potential advantages, challenges such as tumorigenesis risks, delivery complexities, and sustained therapeutic effects persist. Future research should prioritize optimizing stem cell modifications, combining them with current treatments, and conducting large-scale trials to ensure safety and efficacy. Integrating stem cell therapies into GBM treatment could provide more effective and less invasive options for patients.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"699-715"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

UK medical cannabis registry: an updated clinical outcomes analysis of patients with post-traumatic stress disorder. 英国医用大麻登记处：创伤后应激障碍患者的最新临床结果分析。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-05-01 Epub Date: 2025-04-18 DOI: 10.1080/14737175.2025.2490539

Aritra Datta, Simon Erridge, John Warner-Levy, Evonne Clarke, Katy McLachlan, Ross Coomber, Muhammed Asghar, Urmila Bhoskar, Matthieu Crews, Andrea De Angelis, Muhammad Imran, Fariha Kamal, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, Gabriel Shaya, James J Rucker, Mikael H Sodergren

{"title":"UK medical cannabis registry: an updated clinical outcomes analysis of patients with post-traumatic stress disorder.","authors":"Aritra Datta, Simon Erridge, John Warner-Levy, Evonne Clarke, Katy McLachlan, Ross Coomber, Muhammed Asghar, Urmila Bhoskar, Matthieu Crews, Andrea De Angelis, Muhammad Imran, Fariha Kamal, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, Gabriel Shaya, James J Rucker, Mikael H Sodergren","doi":"10.1080/14737175.2025.2490539","DOIUrl":"https://doi.org/10.1080/14737175.2025.2490539","url":null,"abstract":"Background: Cannabis-based medicinal products (CBMPs) are a potential treatment for post-traumatic stress disorder (PTSD), but their long-term efficacy and safety need further investigation. This study assessed the changes in health-related quality of life (HRQoL) and adverse events in PTSD patients prescribed CBMPs.Research design and methods: This observational cohort study included PTSD patients enrolled on the UK Medical Cannabis Registry for 18 months or longer. Changes in PTSD-specific symptoms (IES-R), anxiety (GAD-7), sleep quality (SQS), and general HRQoL (EQ-5D-5 L) were assessed at 1, 3, 6, 12, and 18 months.Results: In 269 patients, significant improvements in PTSD symptoms, anxiety, sleep quality, and HRQoL were observed at all follow-up points (p < 0.001). On multivariate logistic regression, male gender (OR = 0.51; 95% CI:0.28-0.94; p = 0.034) was associated with a reduced chance of reporting improvements in IES-R. Adverse events were reported by 70 (26.02%) patients, with insomnia (n = 42, 15.61%) and fatigue (n = 40, 14.87%) being the most common.Conclusions: CBMPs were associated with improvements in PTSD symptoms, anxiety, sleep, and HRQoL at up to 18 months. Although the study's observational nature limits causal conclusions, these findings support further assessment of medical cannabis.Trial registration: This is an observational study and is not registered as a clinical trial.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":"25 5","pages":"599-607"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0